Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples